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METHODOLOGY ARTICLE Open Access
Iterative feature removal yields highly
discriminative pathways
Stephen O’Hara1, Kun Wang1,6, Richard A Slayden2, Alan R Schenkel2, Greg Huber3, Corey S O’Hern4,
Mark D Shattuck5 and Michael Kirby1*
Abstract
Background: We introduce Iterative Feature Removal (IFR) as an unbiased approach for selecting features with
diagnostic capacity from large data sets. The algorithm is based on recently developed tools in machine learning that
are driven by sparse feature selection goals. When applied to genomic data, our method is designed to identify genes
that can provide deeper insight into complex interactions while remaining directly connected to diagnostic utility. We
contrast this approach with the search for a minimal best set of discriminative genes, which can provide only an
incomplete picture of the biological complexity.
Results: Microarray data sets typically contain far more features (genes) than samples. For this type of data, we
demonstrate that there are many equivalently-predictive subsets of genes. We iteratively train a classifier using
features identified via a sparse support vector machine. At each iteration, we remove all the features that were
previously selected. We found that we could iterate many times before a sustained drop in accuracy occurs, with each
iteration removing approximately 30 genes from consideration. The classification accuracy on test data remains
essentially flat even as hundreds of top-genes are removed.
Our method identifies sets of genes that are highly predictive, even when comprised of genes that individually are
not. Through automated and manual analysis of the selected genes, we demonstrate that the selected features
expose relevant pathways that other approaches would have missed.
Conclusions: Our results challenge the paradigm of using feature selection techniques to design parsimonious
classifiers from microarray and similar high-dimensional, small-sample-size data sets. The fact that there are many
subsets of genes that work equally well to classify the data provides a strong counter-result to the notion that there is
a small number of “top genes” that should be used to build classifiers. In our results, the best classifiers were formed
using genes with limited univariate power, thus illustrating that deeper mining of features using multivariate
techniques is important.
Keywords: Feature selection, Microarray, Discrimination, Classification, Pathways, Sparse SVM, Influenza
Background
The sequencing of complete genomes has accelerated
biomedical research by promising a greater degree of
understanding of the biological processes encoded. The
role of computational biology has become increasingly
important because there is a significant need for progress-
ing beyond statistics and data clustering. New analysis
methods are needed that afford the ability to use more of
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the generated data, thus revealing more insights into bio-
logical processes. Mathematical optimization algorithms,
and related machine learning techniques arising in com-
puter science, have emerged as having significant poten-
tial for knowledge discovery in biological data sets arising
in genomics, metabolomics and proteomics investiga-
tions. These methods are attractive given they are capable
of identifying multivariate interactions associated with
biological complexity, e.g., co-expressing genes in single
or related pathways. Further, the gene selection procedure
is data driven, thus providing an unbiased approach to
knowledge discovery.
© 2013 O’Hara et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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The emphasis on the search for parsimonious models –
that is, models which attain high accuracy while minimiz-
ing the number of features – is now standard operating
procedure in machine learning. Currently, many machine
learning feature selection methods applied to microarray
data explicitly eliminate genes which are redundant, in
terms of discriminative or predictive value, with an exist-
ing set [1-8]. A recurring theme in this body of literature is
to select a small set of “top ranked” genes. Parsimony leads
to computational advantages when analyzing large-scale
data and can improve the signal-to-noise ratio. However,
when applying machine learning methods to biological
data, the advantages of parsimony are less clear.
Microarray data typically includes highly correlated
gene expression levels associated with a (potentially
unknown) biological process. Yet feature selection meth-
ods tend to eliminate genes which fail to provide addi-
tional discriminatory power to the model. To the machine
learning expert, this yields the desired parsimonious
model. To the biologist, the suppression of potentially
biologically-relevant information can impede process
discovery.
We hypothesize that genes selected as most important
to a parsimonious model are in fact only a small subset
of a large set of highly discriminative, and thus informa-
tive, genes. To test this hypothesis, we employ a sparse
Support Vector Machine to build an accurate model using
only a small fraction of the features in the data. We then
repeat this process, but at each iteration we remove all
the genes selected by previous iterations from the data.
At each iteration, the model must be built without the
“most important” genes identified previously. We call this
process Iterative Feature Removal (IFR).
If our hypothesis holds, there should be several itera-
tions where the accuracy remains high, even as the top
genes are iteratively removed from consideration. Eventu-
ally, the process will have removed all the relevant genes,
and the accuracy should fall to random performance.
Our results support this hypothesis. On the evaluated
data sets, IFR demonstrates that at least 20 iterations are
required before we see a significant loss in discriminatory
power, providing hundreds of genes for further analysis.
Results and discussion
Data Sets
For this study, we examine four microarray data sets from
the literature, as summarized in Table 1. The influenza
data is from the Duke pan-viral challenge [9,10]. This
data has gene expression levels taken from peripheral
blood samples of human subjects exposed to H3N2 and
H1N1 influenza. The H3N2 data consists of the gene
expression levels of 12,023 genes collected from 17 human
subjects in approximately 8-hour intervals. The H1N1
data measures the same set of genes, but on a separate
set of 19 subjects, using the same collection method-
ology. In both H3N2 and H1N1, approximately half of
the subjects became symptomatic, the others remained
healthy.
We use two subsets of the influenza data, labeled as
“Influenza 14-16” and “Influenza 11-14” in the table.
The first uses only those samples from time intervals 14
through 16, the second from intervals 11 through 14. The
14-16 data are used in [10], and are claimed to reflect
peak symptom expression in the subjects. We employ this
partition for the purposes of comparison with other pub-
lished results. However, our analysis leads us to believe
that intervals 11-14 represent the true period of peak
symptom expression with the additional benefit of pro-
viding more samples for training and testing. As done
in [9,10], we use the H3N2 data for training and H1N1
is withheld for testing. Data was downloaded from the
Duke websitea.
The other three data sets, lung cancer, prostate cancer,
and BCell lymphoma, were downloaded from the Kent
Ridge Biomedical Data Set Repositoryb. The BCell lym-
phoma data differs from the others in the following ways.
First, it is smaller, both in terms of the number of samples
and the number of features. Secondly, there are missing
values in the data. We replace missing values with the
average expressions for the same gene over all samples.
Thirdly, there is no defined distinction between training
and testing samples. We randomly withheld 25% of the
samples for testing (12 samples of 47 total).
We refer the reader to the original sources, cited in
Table 1, for additional details about the data.
Table 1 Overview of data sets
Data set Training samples Testing samples Features Classes
Influenza 14-16 [10] 51 57 12023 Asymptomatic, Symptomatic
Influenza 11-14 [10] 68 75 12023 Asymptomatic, Symptomatic
Lung Cancer [11] 32 149 12533 Mesothelioma, Adenocarcinoma
Prostate Cancer [12] 102 34 12600 Tumor, Normal
BCell Lymphoma [13] 47 – 4026 Germinal, Activated
Influenza 14-16 and 11-14 represent different temporal intervals of the data from [10]. The former is used to compare with other published results, and the latter is
used because it provides more training samples for the automated analysis. All data sets except the BCell lymphoma have defined training and test partitions.
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Iterative feature removal
Our Iterative Feature Removal (IFR) process works by
repeatedly building a predictive model on training data
using a classifier that assigns non-zero weights to only
a minimal subset of non-redundant features. In other
words, if a gene does not improve the classification accu-
racy, it is not included in this minimal set. At each subse-
quent iteration, we remove all features that were selected
in previous iterations, limiting the model construction to
the remaining features. Thus, we are effectively removing
highly discriminatory genes from the data, and forming a
newmodel without these genes.We observe that for a sur-
prisingly large number of iterations, the resulting model is
essentially as highly discriminatory. For example, we can
remove the best 500 genes whose subsets had accuracies
of over 90% on the influenza testing data, and still dis-
cover new genes that can classify with essentially the same
accuracy.
The genes in each set are selected based on their pre-
dictive power as a group and we observe that they do
not necessarily classify well individually, i.e., they may
not provide univariate separation of the data. In contrast,
they provide a multivariate model for classifying the data
that captures potentially complex biological relationships
amongst the variables.
Given the small number of samples in a high-
dimensional space, model over-fitting is a concern and
must be carefully monitored. At each iteration, we gauge
the quality of the model by testing its accuracy on data
that was not included in the training. A description of the
sparse SVMused for IFR and other methodological details
are provided in theMethods section. Results in Additional
file 1 illustrate that the IFR procedure can be effective even
when using other classification engines.
Figure 1 shows the results of applying IFR to the
influenza and lung cancer data sets. Additional file 1
contains IFR plots for the prostate cancer and BCell
lymphoma data, with the same qualitative characteris-
tics. Additional files 2-5 provide further details of the
results shown in Figure 1. Additional files 6 and 7 provide
the genes selected at each iteration when sparse Logistic
Regression is used instead of SSVM in the IFR process.
The results support our hypothesis that there are many
sets of highly predictive features that can be identified
in the data beyond the first optimal set identified by a
parsimonious model.
Due to the small number of samples, test accuracy
from one iteration to the next can vary substantially.
This is due, in part, to the fact that the genes are being
selected by an optimization criterion on the training
data and, as such, this selection is ignorant of the test
data. It also suggests that, in general, one should avoid
using a hard threshold for stopping the iterative removal
process.
Figure 1 Iterative feature removal on influenza and lung cancer data. Iterative Feature Removal is shown using two data sets, influenza (top)
and lung cancer (bottom). In each row, the left figure shows the accuracy at each iteration and the right figure shows the number of features
selected per iteration. At each iteration, the model is trained without access to any of the genes selected in any of the previous iterations. For the
influenza data set there are about 40 sets that are approximately equally predictive identifying approximately 1200 genes. For the lung cancer data
there are about 30 sets, or some 900 genes that exhibit predictive properties. The red line represents the rolling average accuracy, illustrating the
trend in the data. Figure best viewed in color.
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The interpretation above is complicated by the fact that
when fitting a separating hyperplane to a small number
of points in a high dimensional space, there can be many
equivalently-optimal partitions. There is thus some ele-
ment of luck in model selection when validated against
withheld datac. This effect is less pronounced in the lung
cancer data where there are more test samples. When the
test accuracy is viewed using a rolling average (red line),
the trend becomes clearer.
The training fit (dashed green line) is perfect through
the first 200 or so iterations, even as test accuracy varies
from trial-to-trial. When the training accuracy is 100%
and the test accuracy is low, we infer that the model
is over-fit, meaning that the model does not general-
ize beyond the training data. Genes selected by those
iterations showing model over-fitting are not considered
strongly discriminative in general, and they are consid-
ered to be unrelated to the biology that distinguishes, e.g.,
symptomatic and asymptomatic subjects in the influenza
data.
In the lung cancer data, there is a sharp increase
in test accuracy near the end of the iterations. This
behavior is explained by the uneven distribution of
test samples. Approximately 89% of the test data are
from adenocarcinoma (ADCA) tissue samples. After all
informative genes have been removed using the IFR
process, the training samples can not be accurately
fit to the data (green dashed line), even as the test
accuracy spikes. In this case, a hyperplane has been
constructed such that essentially all points are being clas-
sified as ADCA, which results in an artificially high test
accuracy.
More iterations uncover more biology
We have demonstrated that a significant number of fea-
ture subsets selected via IFR have essentially equivalent
predictive power and hence relate to potentially discrimi-
native biological processes. Our hypothesis suggests that,
in many microarray data sets, there is substantial addi-
tional biological information contained in the features that
remain after the first optimal set is removed. Given that
genes express in pathways, and can be highly correlated,
it is perhaps not surprising that even 20-40 sets can yield
highly accurate predictions. While these genes are redun-
dant from the perspective of machine learning, they are
essential to the process of biological discovery. Since all
the retained sets are predictive, we assert that they play a
role in characterizing the differences between the classes
in the data.
To evaluate how the resulting larger set of informa-
tive genes relates to discriminatory biological pathways,
we follow a two-pronged approach, one relying on man-
ual analysis, the other automated. The first approach uses
manual expert analysis of the features selected using IFR.
The disadvantage of this approach is that it is labor-
intensive and thus difficult to apply to cross-validate
results. The automated approach relies on employing the
Gene Ontology (GO), queried via the GATHER system
[14], to identify pathways associated with sets of genes.
This approach allows us to design a fully-automated sys-
tem and to perform repeated trials with cross-validated
results. The manual approach takes longer and requires
domain expertise, but can yield a more in-depth under-
standing of the biological significance of the gene subsets,
and avoids reporting irrelevant or misleading annotations
that the automated system sometimes provides.
There is some similarity between this knowledge-driven
analysis and feature enrichment strategies, such as Gene
Set Enrichment Analysis (GSEA) [15]. GSEA uses path-
way memberships of selected genes to expand the feature
set to include additional related genes that were not part
of the original selection. In contrast, here we use path-
waymembership knowledge to group only genes that were
selected via IFR, and thus are known to have discrim-
inative power. In the following, we show that grouping
genes according to pathways yields powerful classifiers,
but these classifiers are not the result of enriching the
feature selection.
Manual analysis of genes selected via IFR
We used the influenza 14-16 data for our manual anal-
ysis because this allows for direct comparison to other
published results.
We examined the 40 most predictive iterations from our
IFR process for association with known pathways acti-
vated by influenza infection. This number of iterations
should not be viewed as a hard cutoff and should be driven
to some extent at least by the additional biological infor-
mation being gained. We made our selection by stopping
at the iteration before the consistent decline in test accu-
racy begins, and where the variance in test results remains
relatively low.
As described below, we accumulated related genes
across these predictive sets and organized them by path-
way. As long as the predictive accuracy of a set is high,
the actual iteration that the gene was selected should
not be viewed as a strong indicator of its biological
importance.
Table 2 lists selected biological pathways we found rep-
resented by the set of genes found within the first 40
iterations of IFR. Also shown in the table is the classifi-
cation accuracy of a model built using only the specified
set of genes for each pathway. We find that all pathways
yield quality classification results, and several are highly
accurate, with accuracies on the H1N1 test data over 90%.
Other pathways not listed here may also be present, but an
exhaustive identification is not necessary to support our
hypothesis.
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Table 2 Selected pathways from the first 40 iterations of IFR on the influenza data
Pathway Acc Genes
Interferon Stimulated Genes 87.7 AIM2 (4), DDX60 (3), GBP1 (1), HERC5 (8), HERC6 (17), IFI27 (2), IFI30 (21), IFI35 (18), IFI44 (1), IFI44L (2),
IFI6 (5), IFIH1 (16), IFIT1 (2), IFIT2 (25), IFIT3 (4), IFIT5 (10), IFITM1 (2), IFITM2 (30), IFITM3 (6), IL15 (17),
IL15RA (27), IRF7 (13), IRF9 (12), ISG15 (3), ISG20 (34), MX1 (12), OAS1 (1), OAS2 (10), OAS3 (8), OASL (9),
PSME1 (5), PSME2 (3), RSAD2 (3), STAT1 (7), STAT2 (27), STAT5B (30), TRIM22 (5), XAF1 (9)
Antigen Recognition Genes 93.0 CD1C (17), HLA-B (27), HLA-DOB (6), HLA-DPA1 (32), HLA-DQA1 (3), HLA-DQB1 (6), HLA-E (26),
MICA (22), TAP1 (7), TAP2 (30)
TNF Super Family 89.5 TNF (28), TNFAIP1 (11), TNFAIP3 (29), TNFAIP6 (22), TNFRSF10B (5), TNFRSF14 (31), TNFRSF4 (11),
TNFSF10 (11)
IL-1 Beta Receptor Family 86.0 IL1B (14), IL1F5 (12), IL1R1 (10), IL1RAP (6), IL1RL2 (15), IL33 (24)
B Cell Maturation and Activation 91.2 CD19 (36), CD200 (4), CD22 (10), CD24 (7), CD38 (31), CD40 (23), CD72 (28), CD79A (12), CD86 (16),
CD9 (7), IGHD (12), IGHM (5), IGHV3-23 (15)
Cell Cycle Related 89.5 CDC20 (13), CDC45L (8), CDCA3 (14), CDCA8 (7), CDK5 (1), CDK5R2 (6), CDKAL1 (5), CDKL5 (27),
CDKN1C (13)
Programmed Cell Death 84.2 CASP10 (33), CASP4 (29), CASP5 (24), CASP7 (6), PCDHA3 (14), PCDHGA11 (5), PDCD1LG2 (2),
PDCD4 (14)
Chemokines 87.7 CCL11 (19), CCL5 (36), CCR1 (10), CCR10 (4), CCR3 (29), CCR6 (27), CCRL2 (6), CX3CR1 (35), CXCL10 (30),
CXCL11 (29), CXCL6 (15), CXCR5 (37), DARC (39)
Cell Adhesion Molecules 87.7 ICAM3 (3), ICAM4 (15), ICAM5 (29), MADCAM1 (25)
Cytokine-Cytokine Receptor Signaling 82.5 IL16 (10), IL17RC (26), IL18RAP (1), IL22 (11), IL9 (31), SOCS1 (33), SOCS3 (29), SOCS6 (9)
Complement Pathway 91.2 C1QA (2), C1QB (3), C2 (19), C3AR1 (26), CR2 (12)
Other Immune Response 93.0 CD8A (22), FCER1G (7), FCER2 (28), FCRL2 (14), KIR2DL3 (32), LY6E (1), LY9 (8), MARCO (26), TLR5 (8)
Selected pathways relating to genes taken from the first 40 iterations of IFR on the influenza data. The iteration that the genes were discovered is in parentheses.
Acc indicates the classification accuracy (percent) using only the genes in each list.
Figure 2 shows which pathways were represented by the
genes selected at each iteration. No single pathway was
represented in all iterations, and no single iteration had
representatives from all pathways.
Discussion of selected pathways in influenza data
Several markers of the Interferon pathway were found in
our analysis (Table 2) and the analysis of Chen et al. [10].
The interferon cytokines (α, β , γ , and λ) themselves are
not in this subset, nor did we find them to be in our
most predictive iterations. That may be in part due to the
paracrine, rather than endocrine, nature of these proteins,
and that the samples were blood samples, rather than
samples directly from the site of infection and viral repli-
cation such as the respiratory epithelium. We found many
interferon pathway members OAS1-3, OAS-L, PSME1/2,
ISG20, IFI35, IFI6, IFI30, IFI16, IFIT2 and IFITM2, for
example, all increased in active infection. Interleukin 15
(IL-15) and the IL-15 receptor α chain, which are induced
by the interferons [16], were also found to increase in
symptomatic subjects in our analysis.
Using the 40 most predictive iterations from IFR to look
for more biologically relevant pathways activated by infec-
tion, we noted two other major cytokine pathways, in
particular TNFα and IL-1β also played a role. These two
proinflammatory cytokines are, like the interferons, well
Figure 2 Distribution of selected pathways over IFR iterations on influenza data. The Interferon Stimulated Genes comprise the longest list
and have representation in half of the iterations. Genes from the other pathways require more iterations to discover. Not all iterations cover the
same biological pathways.
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known for their roles in antiviral responses and, in con-
trast to the interferons, have endocrine effects, notably
causing fever [17]. In addition to exploring these path-
ways, we also noted whether these genes were expressed
at higher or lower levels in ill subjects compared to asymp-
tomatic subjects and looked for gene profiles with large
differences in expression levels as these would be both
useful diagnostically as well as give clear indications of
the active pathways. TNFα induced proteins TNFAIP6,
TNFAIP1, and TNFAIP3 as well as TNF super family
10 (TNFSF10) all increased. Additionally, TNF recep-
tor super family 10B (TNFRSF10B) is the receptor for
TRAIL/TNFSF10 but was decreased in symptomatic sub-
jects. Three other TNFRSF members were found to be
highly predictive in this analysis, TNFRSF4 (OX40 recep-
tor), TNFRSF9 (CD137/4-1BB), and TNFRSF14 (HVEM),
although the expression levels between symptomatic and
asymptomatic subjects were only slightly different. All
four TNFRSF members are critical for T cell activation
and maturation [18].
IL-1β , IL-1 receptor type I, IL-1 receptor accessory pro-
tein, and IL-1RL2 were also found to be modulated by
infection. IL-1 receptor type I and IL-1 receptor acces-
sory protein decreased in symptomatic subjects, which is
somewhat paradoxical as these form the receptor com-
plex for IL-1β . Many B cell genes all decreased upon active
infection including IgM heavy chain, IgD heavy chain,
CD9, CD19, CD22, CD24, CD72, CD79A, and CD200.
This may be due to activation and sequestration of B cells
in lymphoid tissues in response to the infection. Simi-
larly, CD8A (primarily expressed on antiviral cytotoxic T
lymphocytes) and Ly9 and KIR2DL3 (markers of antiviral
natural killer cells) also decreased, suggesting that these
cells were also being activated and sequestered in tissues
at the site of infection.
Chemokines and their receptors are also important
small signaling molecules. CXCL10, which activates
chemotaxis in effector T and B increased after infection,
but the neutrophil-specific chemokine CXCL6 decreased.
CCR1 increased with illness, and is a receptor for
many of the CCL chemokines. CCR6, the receptor
for CCL20, decreased upon illness. CCRL2 (chemerin
receptor) also increased [19]. The fractalkine recep-
tor CX3CR1 increased probably due to trafficking of
monocytes [20].
Caspases are involved in apoptotic death of cells.
Caspases CASP4, 5, and 7 all increased. Several Pro-
grammed Cell Death genes, PDCD1LG2, PCDHGA11,
and PCDHA3, also increased in symptomatic subjects.
TLR5 increased in symptomatic subjects, unexpected as
its most well-known ligand is flagellin. Complement com-
ponent C2 decreased, but the complement receptors CR2,
C3AR1 both increased. Chen et al. [10] had also found
C1QA and C1QB as part of their top 50 genes.
Several genes involved in antigen presentation to T lym-
phocytes were also found to be highly predictive. Chen
et al., found TAP1 upregulated in symptomatic sub-
jects, and our analysis also found TAP2. TAP1/2
form a transporter complex to carry peptides into the
endoplasmic reticulum for loading into Class I Major
Histocompatibility Complex (MHC) proteins. MHCClass
I protein/Human Leukocyte Antigen (HLA)-B was also
upregulated in symptomatic subjects, along with the
related protein HLA-E, which is an activator of NK
cells. In contrast, in the Class II chains HLA-DQA1,
HLA-DQB1, HLA-DPA1 and HLA-DOB1 were higher in
asymptomatic subjects.
Combining discriminative pathways
In addition to what has already been described, our
hypothesis further suggests that better diagnostic tools
can potentially be designed by performing a deeper anal-
ysis of the discriminative features selected via IFR. If
true, then certain combinations of features from the dis-
criminative pathways should be able to yield classification
accuracies that exceed any single iteration because we can
improve the signal-to-noise ratio by first selecting dis-
criminative genes and then combining the information
from complementary pathways.
As stated in [21], a necessary and sufficient condition
for an ensemble to be more accurate than any of its con-
stituent classifiers is when the individual classifiers have
predictive power (better than random), and are diverse
(they make different errors). Combining the classifiers
derived from multiple pathways can, in principle, yield a
stronger discriminative model when the pathway-specific
classifiers have uncorrelated errors.
To test whether this is true, we combine pairs of path-
ways and measure the classification accuracy using the
influenza data. We generated a Support Vector Machine
classifier from each pair of pathways listed in Table 2. For
each pair, we combined the features, trained the classi-
fier using the H3N2 data, and measured the classification
accuracy using the H1N1 data. With 12 pathways, there
are 66 unique pairings. The results of the top 16 are shown
in Table 3. The scores for the remaining 50 are available in
Additional file 1. By comparison, Table 4 shows previously
published classification results on the same data using the
same protocol. Several of our single pathway classifiers are
competitive with published results, and all of our top-16
pathway pair classifiers are as good or better, providing
strong evidence for the benefit of IFR for feature selection.
In searching for discriminative pathways using IFR, we
found that we could construct a perfect classifier using
the genes identified with B Cell Maturation and Activa-
tion (BCell) combined with those identified as relating to
Cell Adhesion Molecules (CAM). The classifiers trained
from these two pathways make different errors. The BCell
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Table 3 Accuracies can improvewhen combiningpathways
Acc Pathway pair
100.0 B Cell Maturation and Activation + Cell Adhesion Molecules
98.2 Antigen Recognition Genes + Cell Adhesion Molecules
96.5 IL-1 Beta Receptor Family + Cell Adhesion Molecules
96.5 B Cell Maturation and Activation + Complement Pathway
94.7 IL-1 Beta Receptor Family + B Cell Maturation and Activation
94.7 Cell Cycle Related + Complement Pathway
94.7 Cell Cycle Related + Cell Adhesion Molecules
94.7 Antigen Recognition Genes + B Cell Maturation and Activation
93.0 IL-1 Beta Receptor Family + Complement Pathway
93.0 Complement Pathway + Other Immune Response
93.0 Cell Adhesion Molecules + Other Immune Response
93.0 Cell Adhesion Molecules + Complement Pathway
93.0 B Cell Maturation and Activation + Chemokines
93.0 B Cell Maturation and Activation + Cell Cycle Related
93.0 Antigen Recognition Genes + Other Immune Response
93.0 Antigen Recognition Genes + Complement Pathway
Classification accuracies can improve when combining pathways. We computed
the classification accuracies when using all pairs of the pathway gene lists
presented in Table 2. Top sixteen results are shown.
classifier misses samples: (9,10,11,17,41), while the CAM
classifier misses samples: (1,2,3,4,11,22,33). The only over-
lap between the two sets of errors is sample 11, but when
the two pathways are combined to train a single classifier,
no errors are made.
We computed the t-test scores for all genes in the
influenza data set. Ranked according to t-test, the 17 genes
comprising the combination of the BCell and CAM clas-
sifiers are shown in Table 5. Only one is within the top
200 t-test scores, and only five are within the top 500. In
Table 4 Pathway classification accuracy on influenza
compared to other published results
Acc Classifier
100.0 B cell maturation and activation +
Cell adhesion molecules
93.0 Antigen recognition genes
93.0 Bayesian Elastic Net (from [10])
91.2 Bayesian Lasso (from [10])
93.0 Elastic Net (from [10])
91.2 Lasso (from [10])
91.2 Relevance Vector Machine (from [10])
93.0 SVM-RFE (from [10])
In this table, the accuracy of our best single-pathway and best pathway-pair
classifiers are compared to the best classifiers reported by Chen et al. [10]. The
same protocol is followed: classifiers are trained using H3N2 data from time
intervals 14-16 and tested on H1N1 from the same time period.
fact, all but a few of the pathway and pathway pair clas-
sifiers with high discrimination consist primarily of genes
with relatively low-ranking t-test scores. (See details in
Additional file 1). This highlights the disadvantage of fea-
ture selection methods that start by throwing away “low
ranking” genes. Doing so prevents the discovery of inter-
action effects among genes which are not, by themselves,
discriminative.
Figure 3 compares the genes from the BCell+CAM clas-
sifier to an equal number of the top univariate ranked
genes. The accuracy of a classifier constructed from the
top 17 genes according to t-test ranking is 89.5%, which
is lower than many of the top individual pathway clas-
sifiers and lower than all of the top 16 pathway pair
classifiers. The t-test statistic score for each gene is shown
at the top of the figure in the respective columns. It is
interesting to note that the top univariate genes all have
higher expression levels for symptomatic patients, while
the BCell+CAM genes are mixed.
The weakness in the manual analysis presented herein,
including the results of the pathway and pathway pair
classifiers, is a lack of cross-validation due to the limits
posed by human annotation. We address this limitation
by automating our pathway analysis using queries to the
well-known Gene Ontology database. These results are
presented next.
Automated analysis of genes selected via IFR
As we did in the previous section, we first present the
pathways associated with each iteration of IFR, but this
time the pathway annotations are derived from GO using
the GATHERweb query service.We present the biological
significance of features selected beyond the first optimal
subset in the lung cancer data. As a reminder, this data
consists of two classes of tumors, and so the selected fea-
tures are those that can be used to differentiate between
the two, not to discern whether a tissue sample is can-
cerous. Following that, we present automated pathway
and pathway pair classification using four microarray data
sets.
Gene ontology annotations
The GO annotations associated with the features selected
at each of the first thirty iterations are shown in Figure 4.
To enhance readability, those labels that are represented
by only a few genes across all iterations are not shown.
Complete lists of all genes removed at each iteration are
available in Additional file 1. While some of the annota-
tions provided via automated queries may be irrelevant,
this figure illustrates that different iterations are associ-
ated with different subsets of biological factors. There are
factors that are common to many of the subsets, yet no
single label is present in all iterations.
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Table 5 T-test ranking of genes in the BCell+CAM classifier
Gene IGHM IGHD IGHV3-23 CD200 CD24 CD9 CD22 CD38 CD19
Rank 831 1238 5659 122 348 4620 391 337 508
Gene CD79A CD86 CD40 CD72 ICAM4 ICAM3 ICAM5 MADCAM1
Rank 402 2198 2406 1048 2462 564 4250 8481
The BCell+CAM classifier is 100% accurate on the test data, while consisting of genes that are relatively low ranking in terms of univariate separability. The table shows
gene names and the t-test rankings within the total of 12,023 genes (bold values for those within the first 500). A blank cell separates the 13 BCell genes from the 4
CAM genes.
The annotations in Figure 4 are those from depth 5
in the Gene Ontology structure. The ontology follows a
tree-based organization where lower depths are associ-
ated with more specific labels. Not all genes are annotated
to all depths in the ontology, and thus it is possible to
have no annotations at a given depth for a selected set
of genes, as observed in the figure for iteration 18. We
selected depth 5 for our analysis because it has a balance
between label completeness (many genes have depth-5
labels) and specificity (many depth-5 labels are infor-
mative). The figure suggests that genes associated with
phosphorus metabolism can discriminate between the
two types of lung cancer tumors, as this annotation is rep-
resented in 10 of the 30 iterations. At the same time, none
of the genes known to be associated with phosphorus
metabolism were selected within the first six iterations,
which covers approximately the first 200 selected genes.
Unlike IFR, methods focusing on learning a minimal set of
30-50 discriminative genes (e.g., [4,10]) would be unlikely
to designate this pathway as being discriminative.
By considering a larger pool of correlated genes, a biolo-
gist might discover important information that otherwise
could be masked by feature selection methods optimized
for removing predictive redundancy.
Discriminative pathways
As we did with the manual analysis, we can use our
automated approach to discover discriminative pathways
Figure 3 Univariate separability of discriminative genes. Boxplots show the gene expression levels (as z-scores) between symptomatic and
asymptomatic subjects for selected genes. The first figure shows the expression level for the 17 genes identified by the best pathway pairs classifier
(BCell + CAM). The second figure shows the top 17 genes ranked according to univariate t-test scores. The t-test score is provided at the top of the
figures for each gene. The genes from the best classifier are far less discriminative in the univariate sense than the top ranked genes, but as a group,
they are more discriminative (100% vs. 89.5% classification accuracy). More than two-thirds of the genes from the best classifier fall outside of the
top 500 genes ranked according to t-test.
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Figure 4 Gene ontology annotations per iteration on lung cancer data. The x-axis shows the iteration number, each of which identifies a
subset of approximately 30 genes. The y-axis is a set of labels from the GATHER interface to the Gene Ontology, selecting labels at depth 5 in the
ontology structure. The intensity of the color at an (x,y) location indicates the number of genes in the subset associated with that label. By
comparing one column with another, the results suggest that different iterations contain genes associated with different biological processes. By
comparing one row to another, one can see the distribution of genes over iterations relating to a specific process.
and pathway pairs. Our protocol was to use 50-trial ran-
dom subset cross-validation on the training partition to
identify features associated with the top models. After
selecting the top-performing models from the validation
stage, we then tested on the withheld data. More details
on this procedure can be found in the Methods section.
We also performed the same cross-validation without
using multiple IFR iterations, instead using the sparse
SVM (SSVM) to select the optimal set of features to clas-
sify the data. This is equivalent to using only the first
iteration of IFR. The three methods (pathway, pathway
pair, SSVM) differ in how genes are selected, but a com-
mon classifier engine is used to compare performance.
Once the features are identified, validation and test accu-
racies are computed using a standard (non-sparse) SVM
built from the training data using the selected features,
and evaluated on the validation or test data. Thus, perfor-
mance differs due to the features, not the classifier.
Finally, since there can be several models from the val-
idation trials with near equivalent performance, we also
report on the average test accuracy of the top five models
selected from the validation results.
Table 6 shows that the pathway and pathway pair clas-
sifiers constructed from the genes selected via IFR have
discriminative power comparable to the optimal set of
genes selected by SSVM, over four data sets. Figure 5
shows that the best pathway and pathway pair classifiers
are constructed using genes with generally much lower
univariate power (as measured by t-test ranking) than
those selected by SSVM.
In summary, the pathway, pathway-pair, and SSVM fea-
ture selections were found to perform comparably on the
withheld test data for the lung cancer, prostate cancer,
and BCell lymphoma data sets. There was, however, a sta-
tistically significant improvement using the pathway-pair
features in the influenza data. Significance was measured
using Welch’s two-sample t-test between methods, evalu-
ated on the test accuracies returned by the top five models
from each. P-values for all comparisons can be found in
Additional file 1, with notable results discussed below.
The benefit of using IFR is that several predictive path-
ways can be identified with performance similar to that
of the optimal model, but with the advantage of providing
more insight into the biology of the discriminating factors.
In the lung cancer results, there is some evidence
that pathway-pair feature selection performs better than
SSVM (p-value=0.085), but the p-value is too high to be
conclusive. Since all methods perform well, ceiling effects
may inhibit the ability to differentiate amongst them.
In the influenza 11-14 results, there was strong evidence
that the pathway-pair features yield better classifiers than
those selected via SSVM (p-value=0.0002). Additionally,
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Table 6 Pathway and pathway pair classifiers
Single Pathways Pathway Pairs Sparse SVM
Data Set IFR Iters Val. (μ/σ ) Test Top5 Val. (μ/σ ) Test Top5 Val. (μ/σ ) Test Top5
Lung 30 95.5/7.0 99.3 96.9 98.8/3.7 98.0 98.8 99.8/1.7 98.0 96.8
Influenza 11-14 30 98.6/2.9 96.0 95.5 99.0/2.3 97.3 97.6 98.9/2.3 92.0 92.8
Prostate 30 78.9/14.2 79.4 77.6 81.8/14.0 79.4 78.2 91.0/5.7 79.4 80.6
BCell Lymph. 20 89.5/12.3 83.3 75.0 91.8/12.4 83.3 78.3 87.8/12.4 83.3 80.0
Cross-validated classification results compared using features selected from discriminative pathways and pathway-pairs, and the “optimal” set of features selected by
sparse SVM (SSVM). The latter is equivalent to the first iteration of IFR. The mean and standard deviation of 50 cross-validated trials are shown, followed by the
accuracy of the best model from the validation trials applied to withheld test data. Also shown is the average accuracy of the top 5 models on the withheld test data.
there was some evidence that even individual pathway
features perform better than SSVM (p-value=0.056), and
that genes selected via pathway-pair analysis outperform
those of individual pathways (p-value=0.099). The results
of the automated analysis and the manual analysis when
applied to the influenza data appear to be consistent.
One aspect of the influenza data that is different from
the other three is that the training and validation data
is of a slightly different pathology (H3N2) than the test
data (H1N1).
The results from the prostate data show no statistically-
significant differences among the three methods, even
though the validation distribution for SSVM has a higher
mean accuracy and narrower variance. The features
selected by the top performing pathway, pathway-pair, and
SSVM model yielded classifiers exhibiting the same accu-
racy when tested against the withheld test data, correctly
classifying 27 of 34 test samples (79.4%). The average
test accuracies from the top five models of each method
show no statistically-significant difference. With SSVM,
the accuracy of the cross-validation result appears to over-
estimate the performance of the classifiers when applied
to withheld data. This phenomenon often indicates that
there is a substantial difference in the test data from the
training, and that the model is over-fit to the training data.
From the description of the data as provided by the Kent
Ridge Bio-medical Data Set repository, we note that the
test data was compiled from an independent experiment
from a different lab with different collection methods.
In this case, the pathway-oriented analysis was found to
provide more consistent performance (validation to test-
ing) than the parsimonious features selected via SSVM. A
similar trend was noted for the influenza data.
There is no statistically-significant performance differ-
ences amongst the methods applied to the BCell lym-
phoma data. The top model from each method, when
applied to the withheld test data, correctly classified 10 of
12 samples (83.3%). The BCell lymphoma data only has
12 testing samples, so we observe much higher variance
in classification accuracy, where a single misclassification
Figure 5 T-test gene ranking of top classifiers. The genes from the best model, selected from 50-trial cross-validation, are plotted according to
t-test gene ranking using box plots to show the distributions. As with most parsimonious machine learning methods, the sparse SVM (SSVM)
classifier tends to select genes which are more univariately discriminative than either the pathway or pathway pair classifiers. Deeper mining of the
features using IFR can help identify non-obvious sets of discriminative genes and elucidate discriminative pathways.
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drops the score by over eight percentage points. We note
that for all three methods, the top test performance was
within one standard deviation from the cross-validated
mean. The BCell lymphoma data differs from the rest
in that it is smaller, both in terms of samples and fea-
tures, and it has missing values, which were imputed using
averages.
Conclusions
Existing feature selection methods
Saeys et al. provides a review of feature selection tech-
niques common in bioinformatics [22], categorizing
methods as being filters, wrappers, or embedded. Fil-
ters are feature selection techniques that select features
without reference to a classifier by employing various sta-
tistical analysis techniques. Wrappers are methods that
select potential feature sets and then use a classifier to
determine the quality of the selected features. Embedded
feature selection techniques are those in which the feature
selection is intrinsic to the classifier, such as employing l1
regularization on a linear classifier, resulting in a model
built using only a small number of features (those with
non-zero weights).
A Support Vector Machine (SVM) is a popular machine
learning method that maximizes the width of the mar-
gin surrounding a hyperplane that separates classes of
data [23]. SVMs have shown promise in classifying sam-
ples based on genomic data [2,24,25]. SVMs have also
been employed for feature selection using Wrapper and
Embedded methodologies. SVM-RFE is an SVM-based
feature selection approach that recursively eliminates
genes from the data set that are considered lacking in dis-
criminative power [2]. Similar to our method, SVM-RFE
also iteratively removes genes, but it removes the least
predictive genes until an optimally parsimonious model
is obtained, thereby also eliminating redundant genes.
In contrast, we iteratively remove the best features, i.e.,
most highly discriminatory, in order to demonstrate that
there exist many subsets of highly discriminative genes.
We assemble all sets of discriminatory genes produced
by the iterative removal to form one large set of biologi-
cally important genes. Our perspective is that while genes
may be redundant in terms of a model’s optimization cri-
teria, they are not necessarily biologically redundant, and
may be key to developing a full understanding of the
interacting biological processes.
Redundancy has previously been explored in the con-
text of gene expression data. Yu et al. provide formal
definitions of “strongly relevant,” “weakly relevant,” and
“irrelevant” features [26]. In the context of their discus-
sion, weakly relevant features are redundant with one
or more other features. The approach that we advocate
in this paper suggests that even weakly relevant fea-
tures may have key biological implications. Xing et al.
discusses Markov Blanket Filtering to iteratively remove
redundant features [1]. Yeung et al. points out that there
may be equally discriminative gene subsets, and proposes
a method to select the top genes by applying Bayesian
Model Averaging [4]. However, rather than exploring the
totality of these subsets, they employ Bayesian Model
Averaging to further condense the set of features to the
smallest possible number. As described, their method is
limited to finding the 30 best genes. The authors assert the
advantage of their method is having high prediction accu-
racy while using smaller numbers of genes than competing
methods on several microarray data sets.
Selecting genes by ranking according to a univari-
ate measure is a common practice among biologists.
Significance Analysis of Microarrays (SAM) [27] is a scor-
ing system based on a set of t-test statistics. RankGene
[28] computes gene rankings using any of several possible
univariate measures, including t-test, information gain,
and sum of variances. However, as demonstrated by our
results and Additional file 1, genes with limited univariate
class separation can have substantial predictive power in a
multivariate setting. It is possible that features relating to
complex interaction effects can be missed with univariate
analysis.
Broader impact
What is the goal of feature selection on data sets con-
sisting of a small number of samples of microarray data?
One goal might be the development of a diagnostic tool.
Another goal may be to use the feature selection as an
aid in further discovery and learning about a particular
biological process.
Regarding the first goal, developing a classifier using a
data set with a small number of samples can lead to overly
optimistic results. While the classifier may be able to yield
high accuracy on the test data, little can be said of howwell
it could perform as a diagnostic tool in the general popu-
lation. Imagine developing a decision tree for classifying a
notional influenza data set. With only one question: “does
the subject have a fever?”, the influenza data could be
perfectly partitioned into symptomatic and asymptomatic
patients. Some small set of genes could be identified that
essentially answer this question. While the selected set of
genes may be a perfect classifier on the data set, it would
be useless as a diagnostic tool in the clinic, lacking any
specificity as to the cause of the fever (flu or otherwise). To
restate: identifying a set of features that perfectly separates
test data is not the same as identifying a set of features
that will diagnose a disease in general. The former only
approximates the latter when enough variety is present in
the training data.
Lacking a large sample size, using feature selection
methods to reduce the decision to a small set of features
exacerbates this issue. Training a classifier on a larger set
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of genes is more likely to lead to the development of a
model with greater specificity than training a classifier
using a minimum set of genes found to be discriminative
in the training data. Consider again the example above,
where the classifier learns to partition the data based on
the presence of a fever. If instead the classifier were asked
to fit a much larger set of genes, then more factors would
be involved in the prediction. Instead of generating a false
positive for every patient exhibiting a fever but not having
the flu, themore complexmodel would generate false pos-
itives only for patients having a larger number of factors
similar to the symptomatic training set.
Regarding the second goal, predictive redundancy is
not the same as biological redundancy. For example,
when considering the host response to a pathogen, there
may be several sets of genes which are equally predic-
tive on the test data. One set might relate to the innate
immune response (“Process A”), and another set might
relate to an acquired immune response (“Process B”).
Either set may work for partitioning the test data into
symptomatic/asymptomatic subjects. A feature selection
technique that suppresses redundant features might elim-
inate all genes related to Process B without loss of
predictive accuracy. Yet when the goal is to select fea-
tures to generate insight into the biology, the elimination
of genes associated with Process B is a problem, not
a benefit.
The broader impact of the work presented in this paper
is to challenge the paradigm that seeks to identify a small
number of discriminative features for microarray data, or
other high-dimensional biological data with relatively few
samples. Classifiers built in this way are unlikely to be
useful as diagnostic tools unless they are trained using a
very large number of samples that better approximates the
target population for the tool. Feature selection to aid in
understanding a biological process based on gene expres-
sion data is most useful when a maximally-sized subset of
informative genes can be presented to the researcher.
Summary of significant findings
Iterative Feature Removal provides a process for the
unbiased selection of discriminative sets of features
from a high-dimensional data set. The procedure results
in a deeper mining of relevant information by iter-
atively suppressing top weighted features in order to
unmask the less-obvious features that are nearly equally
discriminative.
We recognize that others have previously observed the
phenomenon where top genes can be removed from a
microarray data set and a subsequent classifier built to
similar accuracy using the remaining set (e.g., Gruvberger
et al. [29]). However we are the first to present a method
for feature selection that leverages this phenomenon as a
core mechanism.
When applied to microarray data, IFR identified sets of
genes that were highly predictive even when the sets were
composed of genes that, taken individually, appear non-
discriminatory. Through automated and manual expert
analysis of the selected genes, we demonstrated that the
selected features exposed biologically-relevant pathways
that other approaches would have missed.
The pathway analysis provides an alternative way of
grouping the genes, as opposed to by ranking, and also
potentially provides more insight to the biologist. By
showing that strong classifiers can be built without con-
sideration to the iteration number or any other ranking
(other than the fact that we selected the gene via IFR), we
prove that strong discriminative power can reside in lower
ranking genes.
Methods
Sparse linear support vector machine
The model for the classifier is a separating hyperplane
f (x) = wTx − b (1)
where x is a vector of gene expression levels. The learning
task is to use labeled observations to determine the
parameters w and b such that unlabeled observations can
be characterized, e.g., as associated with symptomatic or
asymptomatic subjects.
Extending the work of Cortes and Vapnik [23],
Mangasarian proposed [30] an arbitrary norm separating






w · xi + b + ξi ≥ 1, x ∈ S+
w · xi + b − ξi ≤ −1, x ∈ S−
ξ ≥ 0.
(2)
where S+ and S− denote the sets of positive and nega-
tive class samples, respectively. The width of the margin
separating the two classes is 2/‖w‖, which is maximized
when ‖w‖ is minimized. Slack variables, ξi, measure the
degree of misclassification of samples xi. The parameter,
C, determines the penalty assigned to the total error from
misclassified samples, resulting in a trade-off between the
width of the margin and the error penalty.
The p-norm of a vector is defined as ‖w‖p =
(
∑
i |wi|p)1/p. For p = 2, we have the standard SVM.
For p = 1, sparsity is induced in the weight vector w.
In other words, a separating hyperplane is found where
many components of w are essentially zero. We refer to
the solution of Equation (2) with p = 1 as a sparse support
vector machine (SSVM). The sparsity inducing properties
of the 1-norm are nowwell-known; see [31] and references
therein. Our approach follows where the solution to the
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optimization problem given by Equation (2) is determined
using a primal-dual interior point algorithm.
In our gene selection problem, wemay interpret sparsity
as the elimination of genes that are not essential for clas-
sification. This is modeled mathematically by setting the
corresponding weight component to zero. For example, if
gene xi co-expresses with another gene xj then the model
will attempt to set either wi or wj to zero. Both genes may
have high discriminatory value, but they may not both be
needed in a single model since they contain similar infor-
mation. We view one of these genes as a proxy for the
other.
At each iteration of the IFR process, the SSVM deter-
mines a minimal set of genes capable of optimally dis-
criminating the training data using the remaining features.
For reasons described above, in general we do not expect
genes in the same pathway to be found in the same IFR
iteration. Indeed, we see that genes in the same pathway
tend to be spread over many sets as they are iteratively
removed.
When we have a given set of predictive genes and seek
to build a new SVM model, such as when building the
pathway-specific classifiers discussed earlier, we no longer
use the SSVM since we are not implementing feature
selection. In this case we use the p = 2 SVMmodel which
is not parsimonious.
Data pre-processing
For each data set, the source microarray data is normal-
ized to have zeromean and unit deviation for each feature.
For the influenza data, the H3N2 and H1N1 data are
normalized independently, following what was done in
[9,10]. Independent normalization was also employed for
the prostate cancer and BCell lymphoma data sets. For
the lung cancer data, the test data is normalized using
the means and standard deviations of the training data,
which is required because the lung cancer test data has a
highly-skewed class distribution, while the training data
does not.
Parameter selection
We employed cross-validation on the H3N2 data to select
the parameters used by the SVM classifier. We found that
the choice ofC was not sensitive within an order of magni-
tude, and selectedC = 1.0.We employed a tolerance value
of 0.001 for the convergence of the optimization function.
These choices also performed well for the other data sets,
so we employed the same parameters for all.
With SSVM, the weights were determined to be zero
by looking for at least a factor of ten drop in the ratio of
the weights ordered by magnitude. As shown in Figure 6,
the cutoff point where the weights become zero is well-
defined. We note that this behavior is not observed in the
Figure 6 SSVMweights for first IFR iteration.Magnitude of top
200 SSVM weights for the first IFR iteration on the influenza data. The
cutoff for which weights are set to zero is clearly defined by the steep
drop in magnitude.
SVM when a 2-norm is used to minimize the weights in
the optimization problem.
Cross-validation pathway selection
The following provides more detail on how we identi-
fied the pathways and pathway pairs in the cross-validated
automated analysis, as reported in Table 6.
For each data set, we run 50 trials of IFR on a ran-
dom 75/25 percent splits of the training/validation data.
For each trial, we take the first 30 iterations (20 for BCell
lymphoma) to identify the pathways represented by the
selected genes using queries to the Gene Ontology. We
build a classifier by selecting the genes (without enrich-
ment) representing each pathway and compute the vali-
dation accuracy. From one trial to the next, we tend to
find the same discriminatory pathways represented, but
there is some variation to the representative set of genes.
We compute the mean accuracy of a pathway by averaging
the pathway classification results over all trials, using zero
percent accuracy for any trial where a pathway was not
represented. Using these averages over 50 trials, notwith-
standing the fact that there is some variation trial-to-trial
in which genes represent a pathway, we select the top
scoring in terms of mean validation accuracy.
Using the training/validation trials to select a top path-
way (or top 5), we then test how well that pathway classi-
fies the withheld test data. We do this by using the union
of all the discovered genes relating to that pathway over
the 50 trials, creating a new model on the training data,
and reporting accuracy on the test.
A similar procedure is followed for pathway pairs. From
the same 50 trials we already have the individual path-
ways. For each trial, we examine the combinations of those
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pathways that exceed a validation accuracy threshold. The
threshold is used to prevent analyzing a combination
where one pathway is non-discriminative. This thresh-
old saves computation time, but does not change the
results. For each combination, we build a new model on
the training data using the union of the genes from the
two pathways, and record the validation accuracy of the
combination. As we did with the individual pathways, we
compute the average validation accuracy of a pathway pair
over the 50 trials, using zero percent accuracy for any trial
where a pathway pair was not represented. We select the
best pathway pairs using the mean validation scores, gen-
erate new models on the training data using the union of






cThis is not to suggest that random models will classify
this data with any accuracy – they don’t.
Additional files
Additional file 1: Supplemental Material. Additional material and
analysis is available in the supplemental.pdf file.
Additional file 2: IFR_SSVM_H3N2_genes. This file is the
comprehensive list of genes selected at each iteration when using IFR with
SSVM on the influenza data.
Additional file 3: IFR_SSVM_H3N2_acc. This file provides the accuracy
of each iteration of IFR on influenza data using SSVM.
Additional file 4: IFR_SSVM_Lung_genes. This file is the comprehensive
list of genes selected at each iteration when using IFR with the SSVM on
the lung cancer data.
Additional file 5: IFR_SSVM_Lung_acc. This file provides the accuracy of
each iteration of IFR on lung cancer data using SSVM.
Additional file 6: IFR_LR_H3N2. This file is the comprehensive list of
genes selected at each iteration when using IFR with sparse Logistic
Regression on the influenza data.
Additional file 7: IFR_LR_Lung. This file is the comprehensive list of
genes selected at each iteration when using IFR with sparse Logistic
Regression on the lung cancer data.
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